These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 12482329)
1. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329 [No Abstract] [Full Text] [Related]
2. 25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000. D'Orazio AI; Gambill BD Clin Colorectal Cancer; 2001 May; 1(1):10-5. PubMed ID: 12445373 [No Abstract] [Full Text] [Related]
4. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453 [TBL] [Abstract][Full Text] [Related]
5. Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008. Gibson TB; Grothey E; Chu E Clin Colorectal Cancer; 2008 Jul; 7(4):233-9. PubMed ID: 18650191 [No Abstract] [Full Text] [Related]
6. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Moosmann N; Heinemann V Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070 [TBL] [Abstract][Full Text] [Related]
7. Common side effects and interactions of colorectal cancer therapeutic agents. Holt K J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717 [No Abstract] [Full Text] [Related]
8. [Present status of chemotherapy for colorectal cancer in countries outside of Japan]. Doi T; Ohtsu A Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915 [No Abstract] [Full Text] [Related]
10. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. Lee JJ; Chu E Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802 [TBL] [Abstract][Full Text] [Related]
11. [The development of the first line treatment of metastatic colorectal cancer (mCRC)]. Landherr L; Nagykálnai T Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687 [TBL] [Abstract][Full Text] [Related]
12. New developments in systemic chemotherapy in advanced colorectal cancer. Cats A Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888 [TBL] [Abstract][Full Text] [Related]
13. Progress in the development of novel treatments for colorectal cancer. Hoff PM; Pazdur R Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591 [TBL] [Abstract][Full Text] [Related]
14. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study. Chu E Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190 [No Abstract] [Full Text] [Related]
15. [Recent results of irinotecan therapy in colorectal cancer]. Láng I; Hitre E Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572 [TBL] [Abstract][Full Text] [Related]
16. New oxaliplatin-based combinations in the treatment of colorectal cancer. Cassidy J; Hochster H Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555 [TBL] [Abstract][Full Text] [Related]
17. Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer. Clin Colorectal Cancer; 2003 Aug; 3(2):89-91. PubMed ID: 12952563 [No Abstract] [Full Text] [Related]